Effects of chemotherapy upon female fertility

Effects of chemotherapy upon fertility amongst women of reproductive age, using anti-mullerian hormone (AMH) as a marker of ovarian reserve

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN28988709

Enrollment

100

Registered

2010-12-06

Start date

2010-05-26

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: National Cancer Research Network, Reproductive Health

Interventions

1. Medical questionnaire, including questions regarding menstrual cycles, past medical history, desire to have children etc. 2. Venepuncture: serum AMH will be measured in patients before commencing c

patients are recruited at oncology/haematology clinics, or by contacting Midland Fertility Services.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women aged 18 - 43 years 2. Newly diagnosed cancer - mainly with breast cancer and lymphoma

Exclusion criteria

Exclusion criteria: 1. A history of previous exposure to gonadotoxic agents and/or radiotherapy 2. Diagnosed with end stage cancer having a very poor prognosis (less than 10% chances of 1 year survival) 3. Significant ovarian pathology or previous bilateral oophrectomy

Design outcomes

Primary

Measure	Time frame
To assess the impact of different types, doses and duration of chemotherapy on ovarian reserve using AMH, measured at 6, 9, 12 and 60 months	—

Secondary

Measure	Time frame
To assess the accuracy of serum AMH testing in predicting future reproductive capacity, measured at 60 months	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026